转移性透明细胞肾细胞癌患者一线免疫检查点抑制剂后二线VEGFR-TKI治疗的结局
这项回顾性研究分析了70例转移性透明细胞肾细胞癌患者,在一线免疫检查点抑制剂进展后接受二线VEGFR-TKI治疗的疗效与耐受性。45%患者需减量,27%因毒性停药,作者认为二线抗肿瘤活性与耐受性与一线TKI的历史数据相当。
要点
- 中位无进展生存期为13.2个月(95%CI 10.1至未达到)。
- 45%患者需减量,27%因毒性停药,作者认为耐受性与一线TKI历史数据相当。
核心结论
- 在转移性透明细胞肾细胞癌患者中,一线免疫检查点抑制剂后接受二线VEGFR-TKI单药治疗观察到抗肿瘤活性与耐受性,作者认为与一线TKI的历史数据相当。
研究设计与样本
- 回顾性研究,纳入2015年12月至2018年2月在MD Anderson癌症中心或纪念斯隆凯特琳癌症中心接受二线VEGFR-TKI治疗的转移性透明细胞肾细胞癌患者70例。
- 客观缓解由盲法放射科医生按实体瘤疗效评价标准1.1版评估,采用描述性统计和Kaplan-Meier法分析。
主要发现
- 中位年龄59岁;国际转移性数据库联盟预后 favourable-risk 8例(11%)、intermediate-risk 48例(69%)、poor-risk 14例(20%)。
- 一线治疗:抗PD-(L)1单药(纳武利尤单抗或阿替利珠单抗)12例(17%),纳武利尤单抗联合伊匹木单抗33例(47%),抗PD-(L)1联合贝伐珠单抗25例(36%)。
- 二线TKI包括帕唑帕尼、舒尼替尼、阿昔替尼和卡博替尼。
- 二线TKI治疗中,完全缓解1例(1.5%),部分缓解27例(39.7%),疾病稳定36例(52.9%)。
- 中位无进展生存期为13.2个月(95%CI 10.1至未达到)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 本文为回顾性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immune checkpoint inhibitors (ICIs) are being increasingly utilised in the front-line (1L) setting of metastatic clear-cell renal cell carcinoma (mccRCC). Limited data exist on responses and survival on second-line (2L) vascular endothelial growth factor-receptor tyrosine kinase inhibitor (VEGFR-TKI) therapy after 1L ICI therapy. PATIENTS AND METHODS: This is a retrospective study of mccRCC patients treated with 2L VEGFR-TKI after progressive disease (PD) with 1L ICI. Patients were treated at MD Anderson Cancer Center or Memorial Sloan Kettering Cancer Center between December 2015 and February 2018. Objective response was assessed by blinded radiologists' review using Response Evaluation Criteria in Solid Tumours v1.1. Descriptive statistics and Kaplan-Meier method were used. RESULTS: Seventy patients were included in the analysis. Median age at mccRCC diagnosis was 59 years; 8 patients (11%) had international metastatic database consortium favourable-risk disease, 48 (69%) had intermediate-risk disease and 14 (20%) had poor-risk disease. As 1L therapy, 12 patients (17%) received anti-programmed death ligand-1 (PD-(L)1) monotherapy with nivolumab or atezolizumab, 33 (47%) received nivolumab plus ipilimumab and 25 (36%) received combination anti-PD-(L)1 plus bevacizumab. 2L TKI therapies included pazopanib, sunitinib, axitinib and cabozantinib. On 2L TKI therapy, one patient (1.5%) achieved a complete response, 27 patients (39.7%) a partial response and 36 patients (52.9%) stable disease. Median progression-free survival (mPFS) was 13.2 months (95% confidence interval: 10.1, NA). Forty-five percent of subjects required a dose reduction, and twenty-seven percent of patients discontinued treatment because of toxicity. CONCLUSIONS: In this retrospective study of patients with mccRCC receiving 2L TKI monotherapy after 1L ICI, we observed 2L antitumour activity and tolerance comparable to historical data for 1L TKI.
引用
- Shah AY, Kotecha RR, Lemke EA, et al. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors. Eur J Cancer. 2019. PMID: 31075726. doi:10.1016/j.ejca.2019.04.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。